GlobeNewswire Inc | Jan 5, 2021 08:00AM EST

January 05, 2021

REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- BiotricityInc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, announced today that itmadea 510(k)submission to the U.S. Food and Drug Administration (FDA),on December 31 2020,forBiotres.The company expects this process totake at least 4 months,and if theCompanys 510(k) application is cleared bythe FDAthe Company expects a product launchthereafter.

As announced previously,Biotresis a 3-lead patch product for ECG and arrhythmia monitoring for patients at risk for or being diagnosed with certain cardiac issues.Biotrescan work as a Holter, Event Loop, and Extended Holter.

We are excited to announce the 510(k) FDAsubmissionforBiotresand look forward to building out ourproduct offerings further in 2021, statedWaqaasAl Siddiq, CEO of Biotricity. We believe thatBiotresaddresses demand fromsome of our existing customers and a need in theholtermarket.

TheBiotresis aholterproduct that was developed to address the challenges that exist with currentholterpatch products. TheBiotresis designed with the following key features:

-- 3 Channel Recording A wearableholterpatch device that can provide continuous 3 channel recording of ECG (heart) data. All otherholterpatch devices are 1 channel or 2 channels. -- Rechargeable Battery The device can be worn continuously for48 hours, before needing to be charged for 1 hr., enabling continuous data collection for extended periods of time without any intervention, something not possible with traditional holter patch solutions. -- Wireless Connectivity The unique device utilizes Bluetooth technology to offload data, reducing the time for diagnoses. Currentholterpatch solutions can take up to a week before diagnoses are available due to manual data downloading and a lack of connectivity. -- User-Friendly Design Easy to understand and comfortable to wear during regular day-to-day activities.

AboutBiotricityInc.

Biotricityisreformingthe healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trustBiotricitysstandard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.

Important Cautions Regarding Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe ourfuture plans, strategies, and expectations, aregenerally identifiableby use of the words may, should, would, will, could, scheduled, expect, anticipate, estimate, believe, intend,seek, project, or goal or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization ofBiofluxor any of the Companys other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Companys future financial performance, (iv) the regulatory regime in which the Company operates or intends to operateincluding our ability to obtain required regulatory approvalsand (v) the assumptions underlying or relating to any statement described in points (i), (ii)or(iii). Such forward-looking statements are not meant to predict or guarantee actual results, performance,eventsor circumstances and may not be realized because they are based upon the Companys current projections, plans,objectives, beliefs, expectations, estimates and assumptions and are subject toa number ofrisks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statementsas a result ofthese risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Companys inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Companys inability to expand the Companys business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Companys failure to implement the Companys business plans or strategies. These and other factors areidentifiedand described in more detail in the Companys filings with the SEC.The Company assumes no obligation to update any forward-looking statementsin order toreflect any event or circumstance that may arise after the date of this release.

Contacts:Media contactsDonna Loughlin MichaelsLMGPR408.393.5575donna@lmgpr.com

Investor relations:BiotricityInvestor RelationsInvestors@biotricity.com1.800.951.3348